SCHEMBL5496699

SCHEMBL5496699

CCOC(=O)C(Cc1ccncc1)(NC(C)=O)C(=O)OCC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.74
RECQL P46063 1/20 0.74
PKM P14618 2/20 0.54
KDM4E B2RXH2 1/20 0.54
THRB P10828 2/20 0.53
HTT P42858 1/20 0.51
MAPK1 P28482 1/20 0.48
ATM Q13315 2/20 0.48
MAPT P10636 2/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PTPRB P23467 2/20 0.44
MMP8 P22894 1/20 0.42
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
ACP1 P24666 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
NAMPT P43490 3/20 0.40
PPID Q08752 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6870117 0.93 ALDH1A1 (0.69) ALDH1A1RECQLPKMKDM4ETHRB
SCHEMBL11124323 0.85 ALDH1A1 (0.78) ALDH1A1RECQLPKMKDM4ETHRB
SCHEMBL27395266 0.85 ALDH1A1 (1.00) ALDH1A1RECQLPKMKDM4ETHRB
SCHEMBL9556731 0.84 ALDH1A1 (0.76) ALDH1A1RECQLPKMKDM4ETHRB
SCHEMBL6782409 0.84 ALDH1A1 (0.76) ALDH1A1RECQLPKMKDM4ETHRB
SCHEMBL5570727 0.84 ALDH1A1 (0.71) ALDH1A1RECQLPKMKDM4ETHRB
SCHEMBL30476792 0.84 ALDH1A1 (0.71) ALDH1A1RECQLPKMKDM4ETHRB
SCHEMBL10077498 0.83 ALDH1A1 (0.71) ALDH1A1RECQLPKMKDM4ETHRB
SCHEMBL8495876 0.83 ALDH1A1 (0.74) ALDH1A1RECQLPKMKDM4ETHRB
SCHEMBL9556830 0.83 ALDH1A1 (0.74) ALDH1A1RECQLPKMKDM4ETHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288526-B2 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2007-10-30 US disclosed
CN-1288153-C Use of 2-amino-4-pyridylmethyl-dihydrothiazole derivatives as inducible NO-synthase inhibitors AVENTIS PHARMA SA (FR) 2006-12-06 CN disclosed
CN-1602311-A Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase AVENTIS PHARMA SA (FR) 2005-03-30 CN disclosed
EP-1012164-B1 SERINE PROTEASE INHIBITORS AKZO NOBEL NV (NL) 2004-09-22 EP disclosed
US-6762196-B2 ENZYME INHIBITORS OF NITRIC OXIDE SYNTHASE AVENTIS PHARMA S. A. (FR) 2004-07-13 US disclosed
US-20030153605-A1 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase AVENTIS PHARMA S.A. (FR) 2003-08-14 US disclosed
US-20030065185-A1 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2003-04-03 US disclosed
US-6423688-B1 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 ATHENA NEUROSCIENCES, INC. 2002-07-23 US disclosed
US-6218365-B1 FOR TREATING OR PREVENTING A THROMBIN-RELATED DISEASE AKZO NOBEL N.V. (NL) 2001-04-17 US disclosed
CN-1265670-A Dipeptides and related compounds that inhibit VLA-4 mediated leukocyte adhesion ELAND PHARMACEUTICALS CO (US) 2000-09-06 CN disclosed
EP-1012164-A1 SERINE PROTEASE INHIBITORS Akzo Nobel N.V. (NL) 2000-06-28 EP disclosed
EP-1001971-A1 DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 Elan Pharmaceuticals, Inc. (US) 2000-05-24 EP disclosed
WO-1999006432-A1 DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 1999-02-11 WO disclosed
WO-1997031939-A1 SERINE PROTEASE INHIBITORS AKZO NOBEL N.V. (NL) 1997-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065185-A1 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 VCAM1, ICAM1, IL4I1 ALDH1A1 1219/4885RECQL 4579/4885PKM 4109/4885
US-20030153605-A1 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase NOS1, NOS2, NOS3 ALDH1A1 77/4885RECQL 1345/4885PKM 1702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.